Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        141-150 of 367 results

        Refine search

        Research

        Safety and Immunogencity of a Prototype Adjuvanted Inactivated Split-Virus Influenza A (H5N1) Vaccine in Infants and Children

        Highly pathogenic avian influenza A virus (H5N1) is a leading candidate for the next influenza pandemic, and infants and children may play an important role... ...

        Research

        The burden of rotavirus-related illness among young children on the Australian health care system

        To provide estimates of the annual number and cost of hospital admissions, emergency department (ED) visits and general practitioner (GP) visits... ...

        News & Events

        Whooping cough vaccine could be a new weapon in the fight against food allergies

        Researchers from the Telethon Kids Institute and Curtin University will use a $3.9 million grant from the National Health and Medical Research Council to investigate whether a type of whooping cough vaccine could provide bonus protection against food allergies and eczema. ...

        Research

        Safety and Immunogenicity of Early Quadrivalent Influenza Vaccine: A phase 2prospective randomised open-label feasibility study (FluBub)

        Christopher Peter Blyth Richmond CC PC MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP Director, Wesfarmers Centre of Vaccines and Infectious ...

        Research

        Composition of early life leukocyte populations in preterm infants with and without late-onset sepsis

        Composition of leukocyte populations in the first month of life remains incompletely characterised, particularly in preterm infants who go on to develop late-onset sepsis (LOS). The aim of the study was to characterise and compare leukocyte populations in preterm infants with and without LOS during the first month of life. ...

        Research

        An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol

        Invasive meningococcal disease (IMD) causes significant morbidity and mortality worldwide with serogroup B being the predominant serogroup in Australia and other countries for the past few decades. The licensed 4CMenB vaccine is effective in preventing meningococcal B disease. Emerging evidence suggests that although 4CMenB impact on carriage is limited, it may be effective against gonorrhoea due to genetic similarities between Neisseria meningitidis and Neisseria gonorrhoeae. ...

        Research

        Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule

        The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule. ...

        Research

        School-based HPV vaccination positively impacts parents’ attitudes toward adolescent vaccination

        This qualitative study aimed to explore parental attitudes, knowledge and decision-making about HPV vaccination for adolescents in the context of a gender-neutral school-based Australian National Immunisation Program (NIP). Semi-structured interviews with parents of adolescents eligible for HPV vaccination were undertaken as part of an evaluation of a cluster-randomised controlled trial of a complex intervention in 40 schools (2013-2015). ...

        Research

        Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

        Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity. ...

        Research

        Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

        A range of safe and effective vaccines against SARS CoV 2 are needed to address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 vaccine SCB-2019. ...

        Page 15 of 37